CTOs on the Move

Walking Fish Therapeutics

www.walkingfishtx.com

 
Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.walkingfishtx.com
  • 450 East Jamie Court Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.392.0422

Executives

Name Title Contact Details
Nallakkan Arvindan
Chief Technology Officer Profile

Similar Companies

Nordic Naturals

Nordic Naturals is a Watsonville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Helvoet Pharma USA

Helvoet Pharma USA is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NestleHealthScience

Nestle Health Science is pioneering a new field where nutrition becomes therapy. We are changing the course of health through research and innovation, and nutritional therapies. Visit the site to learn more.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Regulatory Professionals Inc

Regulatory Professionals Inc is a Milpitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.